menu
    • menu
    [{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Nadofaragene Firadenovec","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"SK Pharmteco","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SK Pharmteco \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"SK Pharmteco \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Rznomics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SK Pharmteco","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SK Pharmteco \/ Rznomics","highestDevelopmentStatusID":"14","companyTruncated":"SK Pharmteco \/ Rznomics"}]

    Find Clinical Drug Pipeline Developments & Deals by SK Pharmteco

    Menu

    SK Pharmteco

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SK Pharmteco

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            SK Pharmteco

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Rznomics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SK pharmteco and Rznomics Explore Collaboration for RNA-based Gene Therapy Development

                            Details : The collaboration between SK and Rznomics to develop and commercialize multiple gene therapy products & to enable a smooth transition from clinical to full-scale commercial manufacturing.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Rznomics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SK Pharmteco

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            SK Pharmteco

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nadofaragene Firadenovec

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Ferring Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ferring and SK Pharmteco Enter Commercial Gene Therapy Manufacturing Agreement

                            Details : The agreement aims to scale manufacturing for Adstiladrin (nadofaragene firadenovec), an intravesical non-replicating gene therapy approved for BCG-unresponsive non-muscle invasive bladder cancer.

                            Brand Name : Adstiladrin

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 18, 2024

                            Lead Product(s) : Nadofaragene Firadenovec

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Ferring Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth